Biocon Pharma gets US FDA tentative approval for Parkinson's drug

Regulatory product approvalBusiness Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.7%Reaction day

₹392.05

prior close

₹395.20

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.7%-1.0% vs market

Pharmaceuticals peers, median of 156sector-2.0%-0.7% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.1

10m

-1.6

15m

-1.3

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.7-1.7-1.0-2.0-0.7

Next day

-2.1-1.3-0.8-1.3-0.8

-3.6-2.3-1.3-1.4-2.2

-2.4-1.4-1.0-1.0-1.5

-1.7-0.3-1.5-0.8-0.9

-0.5-0.3-0.2-0.6+0.1

-1.3-1.6+0.3-2.1+0.8

15d

-0.2-0.7+0.5-2.1+1.9

-3.7-0.1-3.6-0.8-2.9

-4.9+0.3-5.2-5.2+0.3

-0.5-6.6+6.1-11.8+11.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received tentative approval from the U.S. FDA for its ANDA for Carbidopa and Levodopa Extended-Release Capsules in four strengths (23.75/95 mg, 36.25/145 mg, 48.75/195 mg, and 61.25/245 mg). The product is indicated for treatment of Parkinsons disease, post-encephalitic parkinsonism, and parkinsonism following carbon monoxide or manganese intoxication.

Likely market impact

Positive for Biocon. Reinforces US generics pipeline and subsidiarys presence in the US market ahead of potential commercial launch.